SUSTIVA
LOE ApproachingNDAORALTABLET
Approved
Feb 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
5/8 — Partial
SUSTIVA by Bristol Myers Squibb is [see clinical pharmacology ]. Approved for human immunodeficiency virus type 1 (hiv-1) infection, combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection. First approved in 2002.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUSTIVA is an oral small-molecule tablet approved in 2002 by Bristol Myers Squibb. The generic name and mechanism of action are not disclosed in available data. Patient populations and therapeutic indication require additional reference sources.
$0.025BPart D
LOE ApproachingProduct is in late-stage lifecycle with minimal Part D claims; commercial teams likely focused on managed decline and cost optimization rather than growth.
Mechanism of Action
[see Clinical Pharmacology ].
Worked on SUSTIVA at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.